Advertise with NationWire
728 × 90 Leaderboard
Advertise Here
Science

FDA Rejects Summit’s Ivonescimab Lung Cancer Drug Over Survival Data

Advertise with NationWire
300 × 250 Medium Rectangle
Advertise Here

The US Food and Drug Administration has declined to approve ivonescimab, a lung cancer treatment developed in China and licensed to the Florida-based biotech Summit Therapeutics, after deciding that the drug’s pivotal trial did not show patients lived longer.

Summit announced on Sunday 15 November 2026 that the FDA had issued a Complete Response Letter for its application to approve ivonescimab in combination with platinum-containing chemotherapy.

The decision is a setback for a medicine that had become a symbol of China’s growing role in drug development.

A Complete Response Letter is not a ban, but it means the application cannot be approved in its present form. The FDA’s reasoning, as described by the company, was blunt: slowing a tumour is not the same as extending a life.

What the HARMONi trial showed

The application covered adults with locally advanced or metastatic non-small cell lung cancer carrying mutations in the EGFR gene, whose cancer had progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor — a group with few remaining options.

The evidence rested on the global Phase III HARMONi trial (NCT06396065), published in The Lancet Oncology in 2026. Patients who received ivonescimab plus chemotherapy lived a median of 6.8 months without their disease progressing, compared with 4.4 months for patients who received chemotherapy alone. The combination cut the risk of progression or death by 48 per cent, a hazard ratio of about 0.52.

At a median follow-up of 29.7 months, median overall survival was 16.8 months with ivonescimab plus chemotherapy, against 14.0 months with chemotherapy alone. The hazard ratio for death was 0.79, with a 95 per cent confidence interval of 0.62 to 1.01 — a result that was not statistically significant.

Why survival outweighed slower progression

The distinction sits at the heart of the decision. Progression-free survival measures how long a cancer is held in check; overall survival measures how long patients live. Regulators accept the first as evidence a drug is active, but demand stronger proof of the second.

FDA reviewers concluded that the absence of a survival benefit “does not support the positive benefit-risk profile in support of approval,” STAT reported.

Summit later shared updated June 2026 follow-up data showing a hazard ratio of 0.76 across Asian and Western subgroups — a trend in the drug’s favour, but not enough to change the outcome.

A drug already approved in China

Ivonescimab is a bispecific antibody, designed to attack tumours in two ways at once: by activating the immune system through the PD-1 checkpoint, and by blocking VEGF, a protein that helps tumours grow new blood vessels. It was developed by the Chinese biotech Akeso, which markets it in China, where it was first approved in May 2024. Summit licensed the rights to develop and sell it outside China.

The rejection has drawn added scrutiny because a separate Phase III study conducted entirely in China reported a different result for the same combination. The HARMONi-A trial (NCT05184712), which enrolled 322 patients and was published in JAMA in July 2026, found a positive overall survival result: median survival of 16.8 months with ivonescimab plus chemotherapy, against 14.1 months with chemotherapy alone, a hazard ratio for death of 0.74.

Whether that gap reflects differences in the patient populations, in trial design, or simply in chance is now one of the central questions facing the drug’s developers. No PD-1 and VEGF bispecific antibody is approved in the United States today.

Market reaction and what comes next

Investors reacted sharply. Bloomberg Law reported that Akeso’s shares plunged as much as 32 per cent on Monday after the decision, with chief executive Michelle Xia calling it “the most disheartening moment” in the Chinese biotech’s history.

Summit said it would continue developing ivonescimab, which is being evaluated in 17 late-stage studies spanning lung, colorectal, urothelial and renal cell cancers. A first-line trial, HARMONi-3, is under way, and results from another late-stage study are expected before the end of the year.

The company also has financial backing to keep going. AstraZeneca agreed a $2 billion strategic equity investment in Summit in October 2026, a vote of confidence that now faces its first real test.

The FDA’s decision does not end ivonescimab’s story in the United States. It does make clear, however, that for a drug built on overseas science, American regulators will judge it on American terms — and that slowing a cancer, on its own, is no longer enough.

The decision contrasts with the FDA’s recent approval of Sunharbo, a stroke-prevention drug, and comes as the agency has shelved a fast-track drug voucher programme. Elsewhere in medicine, researchers reported a pill that may cure high blood pressure, a reminder that the regulator’s pipeline is moving on several fronts at once.

Advertise with NationWire
320 × 50 Mobile Banner
Advertise Here

Leave a Reply

Your email address will not be published. Required fields are marked *